Anti-staphylococcal antibodies
This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein MprF. The disclosure further discloses antibodies, which bind to specific extracellular motifs of MprF. The disclosure further relates to therapeutics comprising MprF-specific antibodies and methods of treatment using MprF-specific antibodies or fragments thereof.
1. An antibody or antibody fragment that is specific to an extracellular loop of the multiple peptide resistance factor (MprF) of Staphylococcus aureus , wherein said MprF is of SEQ ID NO:1 or an orthologue of SEQ ID NO: 1, wherein said antibody binds specifically to an extracellular loop of the MprF or the orthologue, wherein said antibody is a monoclonal antibody, chimeric antibody, humanized antibody, synthetic antibody or human monoclonal antibody, or a fragment of said antibody and wherein said antibody or antibody fragment increases susceptibility of a Staphylococcus aureus to a cationic antimicrobial peptide.
2. The antibody or antibody fragment of claim 1 , wherein the cationic antimicrobial peptide is nisin, daptomycin, or cathelicidin.
3. The antibody or antibody fragment according to claim 1 , wherein said antibody binds to the extracellular loop of the MprF, wherein the loop is of the amino acid sequence of ELSGINFKDTLVEFSKINR (SEQ ID NO: 2), YKNYTHDKKKLVHF (SEQ ID NO: 3), SMVRPPDKNNRFVG (SEQ ID NO: 4), LGFKTLGVPEEKV (SEQ ID NO: 5), DALYDGNHLT (SEQ ID NO: 6) or DIYTIEMHTSVLR (SEQ ID NO: 7).
4. The antibody or antibody fragment according to claim 1 , wherein said antibody binds to an isolated peptide of ELSGINFKDTLVEFSKINR (SEQ ID NO: 2), YKNYTHDKKKLVHF (SEQ ID NO: 3), SMVRPPDKNNRFVG (SEQ ID NO: 4), LGFKTLGVPEEKV (SEQ ID NO: 5), DALYDGNHLT (SEQ ID NO: 6) or DIYTIEMHTSVLR (SEQ ID NO: 7).
5. A combination comprising the antibody or antibody fragment according to claim 1 , and a cationic antimicrobial peptide.
6. The combination according to claim 5 , wherein said antimicrobial peptide is a cyclic lipopeptide.
7. The combination according to claim 6 , wherein said cyclic lipopeptide is daptomycin or a daptomycin-related lipopeptide.
8. The combination according to claim 5 , wherein said combination is synergistic.
9. A pharmaceutical composition comprising the combination according to claim 5 .
10. The antibody or antibody fragment according to claim 1 which is an IgG isotype.